Shots:

• The P-II/II EMPATHY study will evaluate the safety & efficacy of ensovibep in patients with COVID-19- who are in the early stages of infection- to prevent worsening symptoms and hospitalization. The P-II study will enroll 400 patients in the P-II part to identify dose- with anticipated results in Aug’2021
• P-III part will be conducted with additional 1-700 patients- with expected results in H1’21. Novartis will lead the clinical program for ensovibep while Molecular Partners will sponsor the studies
• If EMPATHY results are positive- Novartis is planning to seek the FDA’s EUA for the DARPin therapeutic candidate

  Ref: Novartis | Image: Novartis